BioSight
Companies
Annexon, Inc. logo

ANNX

NASDAQBRISBANE, CA
Annexon, Inc.

Annexon develops drug candidates that target the complement system, an immune pathway involved in cell damage and death. The pipeline focuses on neurological and eye diseases where excessive complement activation contributes to disease progression. Annexon is in clinical-stage development, with multiple product candidates in human trials and preclinical programs under investigation.

Price history not yet available for ANNX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar